These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 24692680)

  • 1. The use of bevacizumab in non-small cell lung cancer: an update.
    Lauro S; Onesti CE; Righini R; Marchetti P
    Anticancer Res; 2014 Apr; 34(4):1537-45. PubMed ID: 24692680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
    Lynch TJ; Spigel DR; Brahmer J; Fischbach N; Garst J; Jahanzeb M; Kumar P; Vidaver RM; Wozniak AJ; Fish S; Flick ED; Leon L; Hazard SJ; Kosty MP;
    J Thorac Oncol; 2014 Sep; 9(9):1332-9. PubMed ID: 25122429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
    Kelly K; Huang C
    J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?
    Azim HA; Ganti AK
    Cancer Treat Rev; 2006 Dec; 32(8):630-6. PubMed ID: 17034953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in lung cancer: lackluster performance and unjustified expense?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Sep; 18(3):381-2. PubMed ID: 22777997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor neovasculature in non-small-cell lung cancer.
    Pallis AG; Syrigos KN
    Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
    Gridelli C; Maione P; Rossi A; De Marinis F
    Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab in non-small-cell lung cancer: a review.
    Planchard D
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1163-79. PubMed ID: 21916570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab in non small cell lung cancer.
    Sandler A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.
    Gridelli C; Rossi A
    Oncology (Williston Park); 2010 Nov; 24(13):1216-23. PubMed ID: 21192561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
    J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    Langer C; Soria JC
    Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatments for advanced stage non-small cell lung cancer.
    Stinchcombe TE; Socinski MA
    Proc Am Thorac Soc; 2009 Apr; 6(2):233-41. PubMed ID: 19349493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.